The GAPP Project is funded by the EU-FP7 with the aim to improve the quality of life in children affected by chronic pain. These patients are treated in most cases with drugs which are not authorised for paediatric use. Participants will conduct controlled clinical trials investigating dosage, efficacy and safety of gabapentin for the treatment of paediatric pain.
The article “Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years – evaluation of the safety, […] Read more
The article “Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the […] Read more
The third issue of the GAPP Studies’ newsletter focuses on GABA-1 study and includes an overview on: • regulatory status – agreements – sites activation […] Read more
The second issue of the GAPP Studies’ newsletter focuses only on GABA-1 study and includes an overview on: • regulatory status – agreements – sites […] Read more
Consortium
Newsletter
Please subscribe to the GAPP Project newsletter to receive our latest updates.
